Trials / Conditions / Mild Alzheimer's Disease

Mild Alzheimer's Disease

15 registered clinical trials studyying Mild Alzheimer's Disease — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease NCT05032482	Scion NeuroStim	N/A
Unknown	pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD) NCT05872243	Changping Laboratory	N/A
Recruiting	Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study NCT06058234	Centers for Medicare and Medicaid Services/ Coverage and Analysis Group	—
Recruiting	Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease NCT05417555	University of California, Los Angeles	N/A
Completed	Lomecel-B Effects on Alzheimer's Disease NCT05233774	Longeveron Inc.	Phase 2
Withdrawn	A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age. NCT03752294	University of Rhode Island	Phase 1
Completed	Deferiprone to Delay Dementia (The 3D Study) NCT03234686	Neuroscience Trials Australia	Phase 2
Completed	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's NCT03186989	Ionis Pharmaceuticals, Inc.	Phase 1
Completed	A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impa NCT01548287	AstraZeneca	Phase 2
Terminated	Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease NCT01482013	High Point Pharmaceuticals, LLC.	Phase 1
Completed	An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volun NCT01013610	Link Medicine Corporation	Phase 1
Completed	Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment NCT01061489	University of Konstanz	N/A
Terminated	Effect of AQW051 in Patients With Memory Impairment NCT00582855	Novartis Pharmaceuticals	Phase 2
Completed	Early Detection of Mild Cognitive Impairment in Individual Patients NCT00243451	Louisiana State University Health Sciences Center Shreveport	—
Terminated	Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients NCT00706186	Clayton Sleep Insititute	Phase 4